IRC § 280E, Schedule III, and the New Divide in Cannabis Law
Introduction
For years, Internal Revenue Code section 280E has imposed one of the federal government’s most punishing burdens on the state-legal cannabis industry. Because marijuana has remained a Schedule I controlled substance under federal law, cannabis businesses have generally been denied the ordinary and necessary business deductions available to nearly every other enterprise. See 26 U.S.C. § 280E. The result has been an effective tax burden that often bears little resemblance to actual net income and, in practice, can be confiscatory.
Until today, the industry’s hope for relief rested largely on the still-unfinished federal rulemaking to move marijuana from Schedule I to Schedule III. That framework has now changed. On April 23, 2026, the Department of Justice announced that it had issued a final order, effective April 22, 2026, immediately placing FDA-approved productscontaining marijuana and products containing marijuana subject to a qualifying state-issued medical marijuana license into Schedule III. At the same time, DOJ and DEA announced a new expedited hearing process, beginning June 29, 2026, to consider the broader rescheduling of marijuana from Schedule I to Schedule III.
That development unquestionably alters the legal landscape. But it does not eliminate the need for precision. The immediate Schedule III relief appears to apply to a defined medical subset, not to marijuana across the board. It does not render the broader rescheduling proceeding unnecessary. And it does not disprove the deeper point that federal relief may arrive bundled with a far more medicalized and compliance-heavy regime than much of the existing industry has imagined.
What Section 280E Does
Section 280E provides that no deduction or credit is allowed for amounts paid or incurred in carrying on a trade or business that consists of trafficking in controlled substances prohibited by federal law or by the law of the state in which the business is conducted, where those substances are listed in Schedule I or II of the Controlled Substances Act. 26 U.S.C. § 280E. The provision therefore turns on schedule status. If what is being trafficked is in Schedule I or II, ordinary deductions are generally disallowed; if it is not, the statutory trigger for section 280E is absent.
That is why the industry has watched rescheduling so closely. For cannabis operators, Schedule III has never been merely symbolic. It has been understood as a possible escape from section 280E’s crushing tax consequences. But the word “operators” now needs qualification, because today’s order appears to create a federal distinction between some medical marijuana products and the broader marijuana marketplace.
What Happened Today
DOJ’s press release states that the Acting Attorney General has issued an order “immediately placing both FDA-approved products containing marijuana and marijuana products regulated by a state medical marijuana license in Schedule III of the Controlled Substances Act,” while separately initiating an expedited administrative hearing process on broader marijuana rescheduling. The press release further states that the Department is withdrawing the prior notice of hearing and terminating those earlier proceedings in favor of a new hearing beginning June 29, 2026.
The underlying order is even more consequential than the press release suggests. It describes itself as a final order and states that, effective April 22, 2026, DOJ is placing in Schedule III not only FDA-approved drug products containing marijuana, but also, “in general,” marijuana, marijuana extracts, delta-9-THC, and other compounds derived from the marijuana plant, to the extent they are either included in an FDA-approved drug product or are subject to a state-issued license to manufacture, distribute, and/or dispense marijuana or products containing marijuana for medical purposes. The order also states that it establishes an expedited registration process under 21 C.F.R. part 1301 for entities holding state medical marijuana licenses, enabling them to engage in manufacture, distribution, and dispensing for medical purposes under federal law consistent with treaty obligations.
That is not a press-office flourish. It is a major legal development.
What the Trump Executive Order Did — and Did Not Do
This also clarifies the significance of President Trump’s December 2025 executive order. That order did not itself reschedule marijuana. By its own terms, it directed the Attorney General to take the steps necessary to complete the rulemaking process related to rescheduling marijuana to Schedule III “in the most expeditious manner in accordance with Federal law.” Exec. Order No. 14,370, 90 Fed. Reg. 60,541, 60,542 (Dec. 23, 2025).
That point remains important because the White House’s own public messaging blurred it. A White House “365 Wins in 365 Days” page stated that President Trump “signed an executive order reclassifying marijuana to Schedule III.” But the published executive order said something narrower: it ordered the Executive Branch to complete the existing process. The order controls, not the spin.
Today’s action confirms exactly that sequence. The EO did not itself change schedule status; DOJ later issued a separate final order that did so for a defined category of products, while also restarting the broader hearing process.
Why Today’s Action Matters for Section 280E
The immediate implication is that some cannabis businesses now have a materially stronger argument that section 280E should no longer apply to at least some part of their operations. If a product is now in Schedule III rather than Schedule I or II, the text of section 280E no longer fits that product in the same way. For businesses dealing in FDA-approved marijuana products, the point is relatively straightforward. For businesses operating under qualifying state medical marijuana licenses, the consequence may be much broader.
But here is where the sober analysis starts. Today’s order does not appear to place all marijuana, everywhere, into Schedule III. It draws a line around FDA-approved marijuana products and marijuana products subject to a qualifying state-issued medical license. The broader federal rescheduling question remains pending and will proceed through the new administrative hearing process. So for adult-use markets, non-medical programs, and businesses whose product lines or licenses fall outside the qualifying medical category, section 280E may remain very much alive.
And even for businesses inside state medical systems, there will be serious implementation questions. A business that operates both medical and adult-use lines, or that sells products across different licensing categories, may not find the tax consequences nearly as clean as headline writers assume. That is not because today’s action is trivial. It is because federal tax law, entity structure, and product categorization rarely reward wishful simplification. The new divide is real; its operational consequences will still need to be mapped carefully.
Why This Is Not Broad Federal Legalization
Today’s action also makes something else plain: the federal government is not normalizing cannabis by abandoning control. It is doing almost the opposite. DOJ’s rationale is expressly tied to the United States’ treaty obligations under the Single Convention on Narcotic Drugs and to its authority under 21 U.S.C. § 811(d)(1). The order says that where control of a drug is required by treaty obligations, the Attorney General may issue an order placing that drug in the schedule deemed most appropriate to carry out those obligations, without going through the ordinary findings and procedures otherwise applicable to rulemaking under section 811(a) and (b).
That means today’s move is not a free-market concession. It is a treaty-compliance move. And the order emphasizes exactly what that entails: medical and scientific limitation, licensing of manufacturers and distributors, import and export controls, recordkeeping, quotas, and medical prescriptions for dispensing. Those are not peripheral details. They are the architecture.
In that sense, the pharmaceuticalization concern is no longer speculative. It is embedded in the legal mechanism DOJ has chosen.
Why the Order Strengthens — Not Weakens — the Regulatory Thesis
If anything, today’s action makes the earlier cautionary thesis stronger. The order does not say, in effect, “state medical marijuana exists, therefore federal law will stand aside.” It says, rather, that certain state medical marijuana products can be placed into Schedule III and brought into federal legality through an expedited DEA registration pathway designed to align those programs with federal treaty obligations and controlled-substance rules.
That is a profoundly different conception of federal accommodation. It is not descheduling. It is not cultural recognition. It is not federal acceptance of cannabis on the terms developed by the state-legal industry. It is incorporation into a system of controlled medical distribution under federal supervision.
And that has consequences. Businesses able to operate inside a regime of licensure, registration, inventory control, recordkeeping, medical channels, and eventual prescribing frameworks may benefit enormously. Businesses built around the broader adult-use marketplace, culture-forward retail, or forms of botanical commerce that do not translate neatly into federally supervised medical channels may find themselves increasingly marginal to the federal future taking shape.
Why FDA Approval Still Matters
The FDA question also remains central. The new DOJ action reaches FDA-approved products containing marijuana immediately, which is straightforward enough. But its broader reach to state-licensed medical marijuana does not mean that the FDA has suddenly approved botanical cannabis flower as an ordinary drug product in the conventional sense. Rather, the executive order and DOJ announcement both frame the change as part of a larger effort to improve medical research, strengthen evidence, and address the lack of appropriate guidance for doctors and patients.
That distinction matters. The federal government is not saying that everything presently sold in state dispensaries has been substantively blessed by FDA. It is saying, at least for qualifying medical products, that those products may now be placed in Schedule III and brought under a federally supervised medical structure. There is a difference between tolerance of medical distribution under controlled conditions and full FDA-style product normalization. The former may now be emerging; the latter is still very much a work in progress.
What Happens to the Broader Rescheduling Proceeding
Today’s action does not end the broader fight over marijuana’s overall federal status. DOJ’s press release expressly says that DEA is withdrawing the prior notice of hearing, terminating those proceedings, and initiating a new hearing process beginning June 29, 2026, to consider the proposed rescheduling of marijuana more generally from Schedule I to Schedule III.
So the old point still stands, but in revised form. It is no longer correct to say that nothing has been rescheduled. Something has. But it is also not correct to say that marijuana, full stop, is now in Schedule III. The present reality is bifurcated: immediate Schedule III treatment for FDA-approved marijuana products and qualifying state medical marijuana products, alongside a still-pending administrative process for broader marijuana rescheduling.
What This Means for Cannabis Operators
For operators in state medical programs, today’s action may be the most significant federal development in years. It potentially opens a real argument against ongoing application of section 280E to qualifying medical products and creates a federally recognized path, through expedited registration, for medical manufacture, distribution, and dispensing.
For adult-use operators, the news is more mixed. Today’s order may deepen the divide between medical and adult-use markets, and between operators capable of fitting into a federally controlled medical model and those built for a less formal state-commercial ecosystem. That divide may turn out to be economically, not merely legally, decisive.
For everyone, the compliance burden is going up, not down. The same order that creates immediate Schedule III relief also reinforces the role of DEA registration, treaty-based controls, medical limitation, and lawful distribution under federal supervision. In short: some operators may finally get tax relief, but they are getting it in exchange for a much more legible federal leash.
Conclusion
Today’s DOJ action changes the article, but it does not change its central instinct. Section 280E relief is no longer merely prospective and hypothetical for all cannabis operators. For FDA-approved marijuana products and marijuana products subject to qualifying state medical licenses, DOJ says Schedule III treatment is already in effect. That is a major shift, and it may immediately reshape tax, compliance, and business planning for the medical side of the industry.
But the larger caution remains. This is not blanket marijuana rescheduling. It is not adult-use normalization. It is not a retroactive pardon for old 280E liabilities. And it is not a sign that the federal government has embraced cannabis culture on its own terms. It is, instead, a selective medical reclassification grounded in treaty authority and accompanied by a new, expedited administrative process for the broader question.
So the thesis now becomes sharper, not softer: relief is arriving, but unevenly; and it is arriving through a framework that may reward medicalization, registration, and federal control more than the heterogeneous cannabis marketplace that actually exists. For some operators, that will be a breakthrough. For others, it may be the beginning of a split-screen future in which one part of cannabis enters federal medical legitimacy while the rest remains stuck arguing with section 280E from the outside.
Disclaimer
This article is provided for general informational purposes only and does not constitute legal, tax, or regulatory advice. Cannabis law remains complex and subject to rapid change at both the federal and state levels, and the application of section 280E, the Controlled Substances Act, DEA registration requirements, FDA approval pathways, and related rules depends on the facts of a particular business, product, license, and jurisdiction. Readers should consult qualified counsel and tax professionals before acting on any information discussed here. Viewing this article does not create an attorney-client relationship with Joseph A. Bondy, PLLC.
About Joseph A. Bondy, PLLC
Joseph A. Bondy, PLLC advises clients on cannabis business law, regulatory compliance, and the federal legal and strategic issues affecting operators, investors, and stakeholders in the cannabis industry. The firm’s work includes matters involving rescheduling developments, licensing and enforcement risk, and the shifting intersection of federal policy with state-regulated cannabis markets.
The firm is also positioned to assist businesses in evaluating and navigating the federal government’s newly announced expedited DEA licensing pathway for qualifying medical cannabis activity, together with the related strategic, operational, and regulatory consequences.
To inquire about representation or consultation, please contact Joseph A. Bondy, PLLC through the firm’s website.
